University of Queensland (UQ) start-up BioHerbicides Australia Pty Ltd (BHA) is preparing to launch Australia’s first ‘home-grown’ bioherbicide, thanks to a second Commercialisation Australia grant.
This year’s $451,775 Early Stage Commercialisation grant follows the $50,000 Skills and Knowledge grant BHA received in 2011.
BHA was established by UQ’s main research commercialisation company, UniQuest, in 2010 to commercialise ‘Di-Bak Parkinsonia’, a root and stem-borne, fungal-based bioherbicide, developed by plant pathologist Dr Victor Galea, an Associate Professor in UQ’s Faculty of Science. The technology involves inserting a one-dose gelatine capsule into the tree trunk.
Parkinsonia (Parkinsonia aculeata) is native to the Americas and was introduced to Australia in the late 1800s for ornamental and shade purposes. It has now become one of Australia’s worst woody plant pests.
“We are very pleased to see BHA receive major recognition from the Commonwealth government in the form of half a million dollars to develop this scientific discovery as a commercially available product,” said UniQuest Managing Director, David Henderson.
“It’s a significant local research and development outcome from university-based endeavour, leading to both economic and environmental benefits for a broad cross-section of Australia,” Mr Henderson said.
“Weeds cost the Australian economy $4 billion and Queensland $600 million every year in lost agricultural production. An estimated $60 million per annum is spent on chemicals to control Parkinsonia in Australia. By registering Australia’s first bioherbicide, BHA is likely to gain a significant share of this market while helping land managers gain control over a wide-spread noxious weed.”
The Commercialisation Australia grant will help BHA complete the Australian Pesticide and Veterinary Medicine Authority (APVMA) registration process, optimise operational and processing procedures, and establish strategic relationships with commercial partners keen to market the product to private, corporate and government landholders.
BHA’s bioherbicide has shown potential to overcome the significant physical and economical limitations of current chemical and mechanical Parkinsonia control methods, especially when applied to large areas.
“The environmental impacts of Parkinsonia are considerable. It generally invades waterways first, with infestations expanding outward to wetlands, flood plains and pastures.
“Wetlands are particularly vulnerable because Parkinsonia can impede access to watercourses, contribute to erosion, harbour feral animals, and take over vast tracts of floodplain,” explained Associate Professor Galea.
“Native plant species are replaced, leading to lower quality habitat for animals and impacting on the sustainability of places like national parks, which have high aesthetic, indigenous and tourist value.
“We’ve trialled the science behind the product successfully throughout Queensland and the Northern Territory. The overall infection success was very high, with some treated trees dying within six months, so we believe Di-Bak has the potential to virtually eradicate Parkinsonia from Australia,” Associate Professor Galea said.
APVMA registration for Di-Bak Parkinsonia will be a key achievement for BHA, as it qualifies the product’s safety and scientific claims, making it a more attractive proposition for customers and investors looking to contribute to solving a major environmental problem.
Di-Bak Parkinsonia is one of several bioherbicides BHA plans to develop following confirmation that the technology is transferrable to for other weeds of national significance such as Athol pine, Prickly Acacia and Mimosa. A $300,000 grant from Meat and Livestock Australia (MLA) has enabled UQ to appoint a full-time researcher to assist BHA with further R&D on three large pastoral stations.
Di-Bak Parkinsonia registration and production of pilot batches are expected in 2013.
Commercial enquiries: Craig McDonald +61 7 3365 4037, 0447 248 278 or [email protected]
UniQuest Pty Limited
Established by The University of Queensland in 1984, UniQuest is widely recognised as one of Australia’s largest and most successful university commercialisation groups, benchmarking in the top tier of technology transfer worldwide. From an intellectual property portfolio of 1500+ patents it has created over 70 companies, and since 2000 UniQuest and its start-ups have raised more than A$450 million to take university technologies to market. Annual sales of products using UQ technology and licensed by UniQuest are running at A$3 billion. UniQuest now commercialises innovations developed at The University of Queensland including the Institute for Molecular Bioscience and its commercialisation partner institutions: the University of Wollongong, University of Technology Sydney, James Cook University, University of Tasmania, Mater Medical Research Institute, and Queensland Health. A recent addition to the company is the Queensland Government-supported ilab technology business incubator and accelerator. UniQuest also provides access to an expansive and exclusive network of independent academics to tailor a consulting or project R&D solution to meet the diverse needs of industry and government, facilitating some 500 consulting, expert opinion, testing, and contract research services each year. UniQuest is also a leading Australasian provider of international development assistance recognised for excellence in technical leadership, management and research. Working with agencies such as AusAID, NZAID, the Asian Development Bank and the World Bank, UniQuest has developed and implemented more than 400 projects in 60+ countries throughout the Pacific, South-East Asia, the Indian sub-continent and Africa.
P: +61 7 3365 4037
M: +61 409 767 199